We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.

Delisted

ITCI was delisted on the 1st of April, 2025.

117 hedge funds and large institutions have $476M invested in Intra-Cellular Therapies Inc. in 2017 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 34 increasing their positions, 38 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

52% more call options, than puts

Call options by funds: $4.41M | Put options by funds: $2.9M

5% more capital invested

Capital invested by funds: $454M → $476M (+$22M)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

9% less funds holding

Funds holding: 129117 (-12)

11% less repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 38

32% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 22

Holders
117
Holders Change
-12
Holders Change %
-9.3%
% of All Funds
2.91%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
15
Increased
34
Reduced
38
Closed
22
Calls
$4.41M
Puts
$2.9M
Net Calls
+$1.5M
Net Calls Change
-$2.71M
Name Holding Trade Value Shares
Change
Change in
Stake
California Public Employees Retirement System
51
California Public Employees Retirement System
California
$835K -$33.3K -2,300 -4%
HCM
52
Highbridge Capital Management
New York
$803K +$556K +38,425 +350%
Thrivent Financial for Lutherans
53
Thrivent Financial for Lutherans
Minnesota
$802K
Acadian Asset Management
54
Acadian Asset Management
Massachusetts
$731K +$651K +44,986 New
RhumbLine Advisers
55
RhumbLine Advisers
Massachusetts
$680K +$20.9K +1,445 +4%
Macquarie Group
56
Macquarie Group
Australia
$664K -$38.2K -2,637 -6%
Russell Investments Group
57
Russell Investments Group
United Kingdom
$623K +$20.3K +1,402 +4%
Ohio Public Employees Retirement System (OPERS)
58
Ohio Public Employees Retirement System (OPERS)
Ohio
$622K
New York State Common Retirement Fund
59
New York State Common Retirement Fund
New York
$580K +$14 +1 +0%
PIM
60
Perkins Investment Management
Illinois
$569K
SSA
61
Schonfeld Strategic Advisors
New York
$504K +$448K +30,989 New
GH
62
GAM Holding
Switzerland
$499K
RA
63
Royce & Associates
New York
$488K
D.E. Shaw & Co
64
D.E. Shaw & Co
New York
$474K -$1.29M -89,198 -75%
Bank of Montreal
65
Bank of Montreal
Ontario, Canada
$473K +$369K +25,464 +699%
Invesco
66
Invesco
Georgia
$450K +$401K +27,721 New
Manulife (Manufacturers Life Insurance)
67
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$440K +$52.9K +3,652 +16%
ProShare Advisors
68
ProShare Advisors
Maryland
$439K -$102K -7,053 -21%
FSA
69
Franklin Street Advisors
North Carolina
$423K +$217K +15,000 +136%
NFA
70
Nationwide Fund Advisors
Ohio
$420K -$24.3K -1,681 -6%
MLICM
71
Metropolitan Life Insurance Company (MetLife)
New York
$409K
TI
72
Trexquant Investment
Connecticut
$384K +$342K +23,652 New
Jane Street
73
Jane Street
New York
$375K +$154K +10,609 +85%
Susquehanna International Group
74
Susquehanna International Group
Pennsylvania
$348K -$1.43M -98,820 -82%
AIG
75
American International Group
New York
$343K +$20.2K +1,396 +7%

ITCI Hedge Fund Activity: Q1 2017 in Review

117 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q1 2017, worth a combined $476M — up 4.8% from $454M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of ITCI and 15 opened new positions — a net loss of 7 holders — while 38 trimmed existing stakes and 34 added.

The largest buyer was BlackRock, adding an estimated $51.5M. The largest seller was TimesSquare Capital Management, exiting entirely with an estimated $23.2M sold.

  • 117 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q1 2017, down from 129 in Q4 2016.
  • Funds reported $476M of Intra-Cellular Therapies Inc. stock for Q1 2017, up 4.8% quarter-over-quarter.
  • 15 funds opened new Intra-Cellular Therapies Inc. positions in Q1 2017 and 22 closed out, a net change of -7 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q1 2017 was BlackRock, an estimated $51.5M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q1 2017 was TimesSquare Capital Management, an estimated $23.2M sold.

Based on aggregated 13F filings for Q1 2017.